364 CHAPTER 4.3 Table 2. Continued. Adverse drug event Total MEs Underuse Overuse Misuse ME detectability n (% total) % (n) Drug (n) % (n) Drug (n) % (n) Drug (n) % MEs present during medication review (n) % present MEs detected by STOPP/ START, (n) Confusion/ delirium 1 (1.3) 0.0 (0) N/A 0.0 (0) N/A 100.0 (1) Baclofen (1) 0.0 (0/1) N/A Based on implicit screening questionsa [14] Tremor 2 (2.6) 0.0 (0) N/A 0.0 (0) N/A 100.0 (2) Pregabalinh (1) Lithiumi (1) 100.0 (2/2) 0.0 (0/2) Bradycardia 1 (1.3) 0.0 (0) N/A 100.0 (1) Beta-blocker (1) 0.0 (0) N/A 100.0 (1/1) 100.0 (1/1) Pancreatitis 1 (1.3) 0.0 (0) N/A 0.0 (0) N/A 100.0 (1) Statin (1) 0.0 (0/1) N/A Anaemia 1 (1.3) 0.0 (0) N/A 0.0 (0) N/A 100.0 (1) Acetylsalicylic acid (1) 100.0 (1/1) 100.0 (1/1) Total 77 (100.0) 49.3 (38) 36.4 (28) 14.3 (11) 52.0 (40/77) 60.0 (24/40) aThe complete list of 26 explicit and two implicit screening questions of the DRA adjudication guideline from Thevelin et al. can be found in SI2. bOmitted in systolic heart failure; cIncluding three cases of noncompliance; dOmitted in insulin-dependent Type II diabetes mellitus with poor glycaemic control; eOmitted with concomitant atrial fibrillation; fSubtherapeutic dosage of apixaban; gOveruse in end-stage renal disease (Stage 5); hSupratherapeutic dosage in relation to decreased renal function; iDrug-drug interaction with diuretics. ME = medication error; STOPP = Screening Tool of Older Person’s Prescriptions; START = Screening Tool to Alert doctors to Right Treatment; ACE-I = Angiotensin-converting enzyme inhibitor; NSAID = non-steroid anti-inflammatory drug.
RkJQdWJsaXNoZXIy MTk4NDMw